Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved cisplatin in combination with cytarabine, dexamethasone, and granulocyte colony stimulating factor (G-CSF) (DHAP Therapy) for reimbursement as a treatment option for the treatment of patients with relapsed Non Hodgkin Lymphoma (NHL). The regimen specification also states that rituximab should be included for treatment of CD20 positive patients.
This is written in the approval document as:
Treatment of relapsed Non Hodgkin Lymphoma. Rituximab to be included in CD20 positive patients.
Citation
(R*)-DHAP Therapy, 2022, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/395-r-dhap-therapy.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD20 + | Non-Hodgkin Lymphoma | Cisplatin, Cytarabine, Rituximab |